Drugs / Fluorodeoxyglucose
Fluorodeoxyglucose
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03048097 | Feb 2017 → Jul 2018 | sarcoidosis | Yale University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00368329 | Jun 2006 → Mar 2009 | adenocarcinoma, esophageal cancer, squamous cell carcinoma | Stanford University | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04943211 | Apr 2021 → Jun 2027 expected | histiocytosis | Anna Raciborska | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04901884 | Jun 2021 → Jun 2026 overdue | pulmonary hypertension | University Health Network, Toronto | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorodeoxyglucose | “(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.” NCT04901884 ↗ |
| Known as | 18F-FDG | “determining the efficacy of fluorodeoxyglucose (18F-FDG) in PET-CT imaging” NCT04943211 ↗ |
| Known as | FDG | “[18-F] Fluorodeoxyglucose (FDG)” NCT00368329 ↗ |
| Modality | Diagnostic / imaging agent | “utility of PET-FDG before and after neoadjuvant chemoradiation” NCT00368329 ↗ |
| Route | Intravenous | “5-10 mCi IV administration” NCT00368329 ↗ |